Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article
Madhavan M. et al, (2022), EBioMedicine
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Journal article
Marchevsky NG. et al, (2022), EBioMedicine, 81
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.
Journal article
Sharpe HR. et al, (2022), JCI Insight, 7
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Journal article
Tomic A. et al, (2022), Nat Commun, 13
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Journal article
Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS).
Journal article
Butler C. et al, (2021), Vaccines (Basel), 9
Antibody evasion by the P.1 strain of SARS-CoV-2.
Journal article
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Journal article
Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Journal article
Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Journal article
Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies.
Journal article
Folegatti PM. et al, (2021), Vaccines (Basel), 9
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Journal article
van Doremalen N. et al, (2021), Nature, 590
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Journal article
van Doremalen N. et al, (2020), Nature, 586, 578 - 582
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)
Journal article
Folegatti PM. et al, (2020), LANCET, 396, 466 - 466
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Journal article
Folegatti PM. et al, (2020), Lancet, 396, 467 - 478
Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open-labelled, first-in-human, dose-escalation trial.
Journal article
GILBERT S. et al, (2020), Lancet Infectious Diseases